Karen Mulligan
Karen Mulligan
Sol Price School of Public Policy and Leonard D. Schaffer Center for Health Policy & Economics
Verified email at usc.edu
Title
Cited by
Cited by
Year
Effectiveness of state-level vaccination mandates: evidence from the varicella vaccine
J Abrevaya, K Mulligan
Journal of health economics 30 (5), 966-976, 2011
552011
Access to emergency contraception and its impact on fertility and sexual behavior
K Mulligan
Health economics 25 (4), 455-469, 2016
342016
Contraception use, abortions, and births: the effect of insurance mandates
K Mulligan
Demography 52 (4), 1195-1217, 2015
262015
Value of expanding HCV screening and treatment policies in the United States
MT Linthicum, YS Gonzalez, K Mulligan, GA Moreno, D Dreyfus, T Juday, ...
Am J Manag Care 22 (6), Sp227, 2016
222016
Economic value of anti–vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States
K Mulligan, SA Seabury, PU Dugel, JF Blim, DP Goldman, MS Humayun
Jama Ophthalmology 138 (1), 40-47, 2020
102020
Evaluating HCV screening, linkage to care, and treatment across insurers
K Mulligan, J Sullivan, L Yoon, J Chou, K Van Nuys
Am J Manag Care 24 (8), e257-e64, 2018
82018
Costs and spillover effects of private insurers' coverage of hepatitis C treatment
GA Moreno, K Mulligan, C Huber, MT Linthicum, D Dreyfus, T Juday, ...
Am J Manag Care 22 (6), 2016
82016
The value of progression-free survival in metastatic breast cancer: results from a survey of patients and providers
JP MacEwan, J Doctor, K Mulligan, SG May, K Batt, C Zacker, ...
MDM policy & practice 4 (1), 2381468319855386, 2019
52019
Manufacturer Signal-to-Cutoff Threshold Underestimates Cumulative Incidence of SARS-CoV-2 Infection: Evidence from the Los Angeles Firefighters Study
O Toubat, AH Berg, K Sobhani, K Mulligan, AM Hori, J Bhattacharya, ...
12021
Do companies in the pharmaceutical supply chain earn excess returns?
N Sood, K Mulligan, K Zhong
International journal of health economics and management 21 (1), 99-114, 2021
12021
Examination of universal purchase programs as a driver of vaccine uptake among US States, 1995–2014
K Mulligan, JT Snider, P Arthur, G Frank, M Tebeka, A Walker, J Abrevaya
Vaccine 36 (28), 4032-4038, 2018
12018
Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
K Mulligan, JA Romley, R Myerson
BMC Research Notes 14 (1), 1-5, 2021
2021
Health Technology Assessment in the U.S. – A Vision for the Future
https://healthpolicy.usc.edu/research/health-technology-assessment-in-the-u …, 2021
2021
SARS-CoV-2 Seroprevalence Among Firefighters in Los Angeles, California
K Mulligan, AH Berg, M Eckstein, A Hori, A Rodriguez, O Toubat, N Sood
medRxiv, 2021
2021
New Evidence on the Compensation of Chief Executive Officers at Nonprofit US Hospitals
K Mulligan, S Choksy, C Ishitani, JA Romley
Medical Care Research and Review 77 (5), 498-506, 2020
2020
THE VALUE OF TREATMENT FOR COVID-19
K Mulligan, K Van Nuys, D Peneva, M Ryan, G Joyce
2020
HEALTH TECHNOLOGY ASSESSMENT FOR THE US HEALTHCARE SYSTEM
K Mulligan, D Lakdawalla, PJ Neumann, GR Wilensky, DP Goldman, ...
2020
HOSPITAL SYSTEM PARTICIPATION AND HOSPITAL SPENDING
K Mulligan, J Romley, S Choksy, MPPC Ishitani
2019
FUTURE HEALTH DIVIDENDS FOR CALIFORNIA
B Tysinger, K Mulligan, H Zhao, A Cassil, D Goldman
2019
Evaluating the Hepatitis C screening-to-treatment continuum in a federally qualified health center
L Yoon, K Mulligan, J Sullivan, K Van Nuys, J Chou
APHA 2017 Annual Meeting & Expo (Nov. 4-Nov. 8), 2017
2017
The system can't perform the operation now. Try again later.
Articles 1–20